Pharmacokinetic/Pharmacodynamic modeling of abexinostat-induced thrombocytopenia across different patient populations: application for the determination of the maximum tolerated doses in both lymphoma and solid tumour patients

Thrombopoietin from beginning to end

(2014) Ian S. Hitchcock et al.   BRITISH JOURNAL OF HAEMATOLOGY

Pharmacokinetic/pharmacodynamic modelling-based optimisation of administration schedule for the histone deacetylase inhibitor abexinostat (S78454/PCI-24781) in phase I

(2013) Sylvain Fouliard et al.   EUROPEAN JOURNAL OF CANCER

Modified Toxicity Probability Interval Design: A Safer and More Reliable Method Than the 3 + 3 Design for Practical Phase I Trials

(2013) Yuan Ji et al.   JOURNAL OF CLINICAL ONCOLOGY

Application of Hematological Toxicity Modeling in Clinical Development of Abexinostat (S-78454, PCI-24781), A New Histone Deacetylase Inhibitor

(2013) Quentin Chalret du Rieu et al.   PHARMACEUTICAL RESEARCH

Thrombocytopenia induced by the histone deacetylase inhibitor abexinostat involves p53-dependent and -independent mechanisms

(2013) A Ali et al.   Cell Death & Disease

Deciphering the molecular and biologic processes that mediate histone deacetylase inhibitor-induced thrombocytopenia

(2011) M. J. Bishton et al.   BLOOD

Automatic data binning for improved visual diagnosis of pharmacometric models

(2011) Marc Lavielle et al.   JOURNAL OF PHARMACOKINETICS AND PHARMACODYNAMICS

A simultaneous analysis of the time-course of leukocytes and neutrophils following docetaxel administration using a semi-mechanistic myelosuppression model

(2010) Angelica Linnea Quartino et al.   INVESTIGATIONAL NEW DRUGS

Clinical Studies of Histone Deacetylase Inhibitors

(2009) H. M. Prince et al.   CLINICAL CANCER RESEARCH

Histone deacetylase inhibitors: Potential in cancer therapy

(2009) P.A. Marks et al.   JOURNAL OF CELLULAR BIOCHEMISTRY

Evaluation of different tests based on observations for external model evaluation of population analyses

(2009) Karl Brendel et al.   JOURNAL OF PHARMACOKINETICS AND PHARMACODYNAMICS

Dose Escalation Methods in Phase I Cancer Clinical Trials

(2009) Christophe Le Tourneau et al.   JNCI-Journal of the National Cancer Institute

Computing normalised prediction distribution errors to evaluate nonlinear mixed-effect models: The npde add-on package for R

(2008) Emmanuelle Comets et al.   COMPUTER METHODS AND PROGRAMS IN BIOMEDICINE

Challenges and Pitfalls of Combining Targeted Agents in Phase I Studies

(2008) Stephen A. Cannistra   JOURNAL OF CLINICAL ONCOLOGY

Extensions to the Visual Predictive Check to facilitate model performance evaluation

(2008) Teun M. Post et al.   JOURNAL OF PHARMACOKINETICS AND PHARMACODYNAMICS